[go: up one dir, main page]

MA33991B1 - Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire - Google Patents

Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire

Info

Publication number
MA33991B1
MA33991B1 MA35126A MA35126A MA33991B1 MA 33991 B1 MA33991 B1 MA 33991B1 MA 35126 A MA35126 A MA 35126A MA 35126 A MA35126 A MA 35126A MA 33991 B1 MA33991 B1 MA 33991B1
Authority
MA
Morocco
Prior art keywords
disorders
treatment
vascular leak
ocular angiogenesis
patient
Prior art date
Application number
MA35126A
Other languages
Arabic (ar)
English (en)
Inventor
Valeriu Damian-Iordache
Andrew King
Megan M Mclaughlin
Albert B Suttle
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of MA33991B1 publication Critical patent/MA33991B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement des troubles de l'angiogenèse oculaire ou de la fuite vasculaire chez un patient, grâce à l'administration d'inhibiteurs appropriés, dont le pazopanib ou des hydrates ou des sels pharmaceutiquement acceptables de celui-ci.
MA35126A 2010-01-06 2011-01-05 Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire MA33991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29274710P 2010-01-06 2010-01-06
PCT/US2011/020231 WO2011085007A1 (fr) 2010-01-06 2011-01-05 Méthode de traitement

Publications (1)

Publication Number Publication Date
MA33991B1 true MA33991B1 (fr) 2013-02-01

Family

ID=44305773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35126A MA33991B1 (fr) 2010-01-06 2011-01-05 Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire

Country Status (21)

Country Link
US (1) US20130012531A1 (fr)
EP (1) EP2521550A4 (fr)
JP (1) JP2013516472A (fr)
KR (1) KR20120125244A (fr)
CN (1) CN102781450A (fr)
AU (1) AU2011203706A1 (fr)
BR (1) BR112012016673A2 (fr)
CA (1) CA2786328A1 (fr)
CL (1) CL2012001852A1 (fr)
CO (1) CO6561789A2 (fr)
DO (1) DOP2012000174A (fr)
EA (1) EA201290603A1 (fr)
IL (1) IL220594A0 (fr)
MA (1) MA33991B1 (fr)
MX (1) MX2012007875A (fr)
PE (1) PE20121523A1 (fr)
PH (1) PH12012501358A1 (fr)
SG (1) SG181826A1 (fr)
TW (1) TW201201808A (fr)
UY (1) UY33164A (fr)
WO (1) WO2011085007A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201206908A (en) * 2010-05-05 2012-02-16 Glaxo Wellcome Mfg Pte Ltd Pharmaceutical compositions and methods of making same
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (fr) 2011-08-05 2015-08-12 Forsight Vision4 Inc Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable
JP2015523546A (ja) * 2012-05-01 2015-08-13 トランスレイタム メディカス インコーポレイテッド 失明性疾患を処置および診断するための方法
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
CA2957548A1 (fr) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Formulations stables et solubles d'inhibiteurs de la tyrosine kinase de recepteurs, et procedes de preparation de ces dernieres
EP3302379B1 (fr) 2015-06-06 2023-11-22 Cloudbreak Therapeutics, LLC Compositions et méthodes pour le traitement du ptérygion
US10323349B2 (en) * 2015-09-25 2019-06-18 Kyoudojyutaku Co., Ltd. Washing system
KR102408596B1 (ko) 2016-06-02 2022-06-13 에이디에스 테라퓨틱스 엘엘씨 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법
US11753382B2 (en) 2019-06-25 2023-09-12 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304059B6 (cs) * 2000-12-21 2013-09-11 Glaxo Group Limited Deriváty pyrimidinu a farmaceutický prostredek
PL1968594T3 (pl) * 2005-11-29 2011-03-31 Glaxosmithkline Llc Leczenie zaburzeń neowaskularyzacyjnych oka, takich jak zwyrodnienie plamki żółtej, rozszerzenie naczyń siatkówki w zespole Hippla i Lindaua, zapalenie błony naczyniowej oka i obrzęk plamki
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
EP2453748A4 (fr) * 2009-07-16 2013-01-02 Glaxo Wellcome Mfg Pte Ltd Méthode de traitement

Also Published As

Publication number Publication date
EA201290603A1 (ru) 2013-03-29
WO2011085007A1 (fr) 2011-07-14
CA2786328A1 (fr) 2011-07-14
DOP2012000174A (es) 2012-12-15
SG181826A1 (en) 2012-07-30
CO6561789A2 (es) 2012-11-15
IL220594A0 (en) 2012-08-30
UY33164A (es) 2011-08-31
EP2521550A4 (fr) 2013-07-03
AU2011203706A1 (en) 2012-07-12
CN102781450A (zh) 2012-11-14
PH12012501358A1 (en) 2019-03-22
TW201201808A (en) 2012-01-16
BR112012016673A2 (pt) 2018-06-05
JP2013516472A (ja) 2013-05-13
PE20121523A1 (es) 2012-12-12
KR20120125244A (ko) 2012-11-14
EP2521550A1 (fr) 2012-11-14
US20130012531A1 (en) 2013-01-10
CL2012001852A1 (es) 2012-11-30
MX2012007875A (es) 2012-08-03

Similar Documents

Publication Publication Date Title
MA33991B1 (fr) Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
EA201790653A1 (ru) Способ лечения болезни альцгеймера и других расстройств
EA201500362A1 (ru) Ингибиторы rho-киназы
EA201301354A1 (ru) Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
MY170198A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
MX351230B (es) Formulacion oftalmica y metodo para mitigar la presbicia.
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201491460A1 (ru) ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
WO2012080497A3 (fr) Procédés de traitement et de prévention de maladies oculaires
EA201190337A1 (ru) Способ лечения
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
EP2796450A4 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse
EP2513336A4 (fr) Procédé pour caractériser la fonction immunitaire de l'hôte par induction ex vivo de marqueurs immunitaires offensifs et défensifs
PH12013501509A1 (en) Treatment of cognitive dysfunction in schizophrenia
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
EA201490173A1 (ru) Фармацевтическая композиция для лечения преждевременной эякуляции и способ лечения преждевременной эякуляции